Proteome Sciences has moved biomarker research in Alzheimer's disease a step further with the conclusion of a validation study. The project, carried out in collaboration with the National Institute for Health Research Biomedical Research Centre for Mental Health and Merck Millipore, looked at a thousand samples and identified three biomarker panels of 11 to 16 proteins that are able to pick out people with mild cognitive impairment or Alzheimer's disease, as well as healthy individuals. "Our analysis of the data from this large study provides individual markers and defined marker panels that have good diagnostic and prognostic utility," explained Proteome CEO Christopher Pearce. "Given the complexity of the data, we expect that the full analysis will introduce further biomarkers to the three panels announced today over the coming months and we are hopeful that collectively these will benefit patients and families suffering from the devastating effects of Alzheimer's." Press release